Buy Anti-HPV16 L1/Major capsid protein L1 Antibody (H16.V5)

Catalog No.

RVV08805

Expression system

Mammalian Cells

Species reactivity

Human papillomavirus type 16

Host species

Mouse

Isotype

IgG1, kappa

Clonality

Monoclonal

Applications

ELISA, Neutralization, WB

Target

L1, Major capsid protein L1

Concentration

1.93 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P03101

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

H16.V5

Note

For research use only.

SDS-PAGE

SDS PAGE for HPV16 L1/Major capsid protein L1 Antibody (H16.V5)
Western Blot

Figure 4: Two-step purification of L1 removes bulk of cellular protein. Analysis of L1 and residual cellular host proteins during purification under reducing conditions via Western blot and Coomassie-stained SDS-PAGE (12% Bis-Tris gel). After precipitation with 45% AMS, the filtered sample was subjected to cation exchange chromatography (CaEx) for final purification. Column-bound L1 eluted at 1 M NaCl in fractions E4 - E8. The asterisk in the Coomassie-stained SDS-PAGE marks the band referring to HPV-16 L1. 50 ng S. cerevisiae-produced L1 served as a positive control and Physcomitrella wildtype as a negative control.
Data sourced from citation (PMID: 40960656)
Western Blot

Ammonium sulphate precipitation of L1 from moss extracts. Samples from the supernatant and the resuspended and dialysed pellet before and after filtration were analysed for the presence of L1 content and residual host proteins under reducing conditions via Western blot and Coomassie-stained gel, respectively. CTP-pL1 30 extracts were precipitated with either 40%, 45%, or 50% ammonium sulphate (AMS). After centrifugation, the supernatant and the precipitate were taken up and dialysed against cation exchange chromatography binding buffer to remove excess AMS. Non-dissolved protein was cleared from the sample using 0.22 µm filters. 45% AMS was found to be sufficient for full precipitation of L1 from crude extracts. 30 ng S. cerevisiae-produced L1 served as a positive control and Physcomitrella wildtype as a negative control.
Data sourced from citation (PMID: 40960656)
Dot Blot

Figure 5: Moss-produced HPV-16 L1 assembles into capsomers, which are stable throughout purification. Dot blots were performed using two different antibodies to analyse the formation of capsomers in yeast-produced L1 and samples from CTP- pL1 30 purification (extract, after AMS precipitation, elution) and dis- and reassembly. The CamVir1 antibody detects a linear epitope in both denatured and native L1. The neutralizing antibody H16.V5 detects specifically conformational epitopes in L1 capsomers and VLPs. Positive H16.V5 signals indicate HPV-16 L1 monomers to assemble at least into capsomers, in vivo or after extraction, which are stable throughout the purification. The experiment only allows qualitative but not quantitative comparison since sample concentrations were adjusted individually. `L1 denatured´ was incubated at 95 °C for 5 min, all other samples were kept at 4 °C. A wildtype sample was used as a negative control.
Data sourced from citation (PMID: 40960656)

Mapping the B cell epitopes within the major capsid protein L1 of human papillomavirus type 16., PMID:29959021

L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine., PMID:29984037

VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris., PMID:30091403

Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid., PMID:30287156

A Novel Human Papillomavirus 16 L1 Pentamer-Loaded Hybrid Particles Vaccine System: Influence of Size on Immune Responses., PMID:30360122

Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity., PMID:30560935

Post-treatment human papillomavirus antibody kinetics in cervical cancer patients., PMID:30955486

Phosphorylation of Human Papillomavirus Type 16 L2 Contributes to Efficient Virus Infectious Entry., PMID:30996086

Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity., PMID:31147274

Effective Neutralizing Antibody Produced in Mice Directly Immunized with Integrated Pichia pastoris Expressing HPV16L1 Protein., PMID:31381497

Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines., PMID:31994744

Simultaneous quantification of major capsid protein of human papillomavirus 16 and human papillomavirus 18 in multivalent human papillomavirus vaccines by liquid chromatography-tandem mass spectrometry., PMID:32067760

The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease., PMID:32133000

Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens., PMID:32510304

DRH1 - a novel blood-based HPV tumour marker., PMID:32535546

Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women., PMID:32727491

Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes., PMID:32967963

Phylogeny and In Silico Structure Analysis of Major Capsid Protein (L1) Human Papillomavirus 45 from Indonesian Isolates., PMID:32986347

Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test., PMID:33249381

Response to: "Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test"., PMID:33254024

Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists., PMID:33309485

Identification of the mimotopes within the major capsid protein L1 of human papillomavirus types 18 and 45, using neutralizing monoclonal antibodies., PMID:33493568

Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP., PMID:33573433

In silico prediction of T-cell and B-cell epitopes of human papillomavirus type 16 L1 protein., PMID:33624357

Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency., PMID:33636291

Inducible expression of human papillomavirus-16 L1 capsomeres in the plastomes of Nicotiana tabacum: Transplastomic plants develop normal flowers and pollen., PMID:33650709

RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates., PMID:33802456

The Synthesis of Main Capsid Protein of Anogenital Type HPV6 L1 in Plant Expression System on the Basis of Tomato Fruits., PMID:34189649

Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy., PMID:34635698

Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer., PMID:34642315

Genetic variability in minor capsid protein (L2 gene) of human papillomavirus type 16 among Indian women., PMID:35552511

Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway., PMID:35619167

RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer., PMID:35703545

Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development., PMID:36263027

Serologic Response to Human Papillomavirus Genotypes Among Unvaccinated Women: Findings From the HITCH Cohort Study., PMID:36322543

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice., PMID:36679860

Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas., PMID:36680181

Human papilloma virus-16-specific CD8+ T-cell expansions characterize different clinical forms of lichen planus and not lichen sclerosus et atrophicus., PMID:36922453

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination., PMID:36922512

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice., PMID:37175776

Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope., PMID:37798448

Nano-Sized Chimeric Human Papillomavirus-16 L1 Virus-like Particles Displaying Mycobacterium tuberculosis Antigen Ag85B Enhance Ag85B-Specific Immune Responses in Female C57BL/c Mice., PMID:37896900

A validated polyclonal antiserum-based immunoassay for assessment of HPV 16 L1 relative potency., PMID:38340596

Prevalence of HPV16 L1 protein in oral biopsies: A diagnostic study from Ecuador., PMID:39018933

Design and antiviral assessment of a panel of fusion proteins targeting human papillomavirus type 16., PMID:39453911

[A fluorescence immunochromatography method for detection of human papillomavirus type 16 E6 and L1 proteins]., PMID:39584350

Molecular epidemiology of human papillomavirus variants in cervical cancer in India., PMID:39913513

A novel fluorescence immunoassay for the quantitative detection of HPV16 L1 antibodies in human serum samples using ZnCdSe/ZnS quantum dot-labeled antibodies., PMID:40197040

HPV16 neutralizing monoclonal antibodies show evidence for common developmental pathways and public epitopes., PMID:40236113

All-atom MD simulations of the HPV16 capsid., PMID:40475506

Production of HPV-16 L1 virus-like particles in Physcomitrella photobioreactors. [RVV08805]

Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. PMID: 14505089

Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. PMID: 12857908

Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. PMID: 11878901

Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. PMID: 18388490

Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples. PMID: 17012876

Immunization with Human Papillomavirus 16 L1+E2 Chimeric Capsomers Elicits Cellular Immune Response and Antitumor Activity in a Mouse Model. PMID: 27058179

Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. PMID: 14557648

Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. PMID: 16391114

Transient expression of Human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector. PMID: 16530873

Development and Characterization of an HPV Type-16 Specific Modified DNA Aptamer for the Improvement of Potency Assays. PMID: 28233502

Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles. PMID: 17577054

Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. PMID: 17325351

The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles. PMID: 22563414

A deletion and point mutation study of the human papillomavirus type 16 major capsid gene. PMID: 16938363

Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy. PMID: 24299977

Quantitation and biospecific identification of virus-like particles of human papillomavirus by capillary electrophoresis. PMID: 28841998

Development of a non-denaturing electrophoresis system for characterization of neutralizing epitopes on HPV virus-like particles. PMID: 17137641

Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11. PMID: 12832218

Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36. PMID: 29125554

Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. PMID: 9223527

Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. PMID: 22356831

Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. PMID: 10233949

High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16. PMID: 29211035

A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5. PMID: 26750243

A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment. PMID: 25392224

Document Download

Anti-HPV16 L1/Major capsid protein L1 Antibody (H16.V5).pdf

Anti-HPV16 L1/Major capsid protein L1 Antibody (H16.V5)